


**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:




1. (Currently amended) A compound of the formula (I):



and pharmaceutically acceptable salts thereof;

wherein:

A is  $R'-C(O)-$ , wherein  $R'$  is ~~selected from  $R^1-$~~   
 ~~$C_4-C_6$  alkyl,~~



~~or~~

~~or~~

;

each  $R^1$  is independently selected from  $-C(O)-$ ,  $-S(O)_2-$ ,  $-C(O)-C(O)-$ ,  $-O-C(O)-$ ,  $-O-S(O)_2-$ ,  $-NR^2-$ ,  $-NR^2-S(O)_2-$ ,  $-NR^2-C(O)-$  or  $-NR^2-C(O)-C(O)-$ ;

each  $H_t$  is independently selected from  $C_3-C_7$  cycloalkyl;  $C_5-C_7$  cycloalkenyl;  $C_6-C_{14}$  aryl; or a 5-7 membered

saturated or unsaturated heterocycle, containing one or more heteroatoms selected from N, N(R<sup>2</sup>), O, S and S(O)<sub>n</sub>; wherein said aryl or said heterocycle is optionally fused to Q; and wherein any member of said Ht is optionally substituted with one or more substituents independently selected from oxo, -OR<sup>2</sup>, SR<sup>2</sup>, -R<sup>2</sup>, -N(R<sup>2</sup>)(R<sup>2</sup>), -R<sup>2</sup>-OH, -CN, -CO<sub>2</sub>R<sup>2</sup>, -C(O)-N(R<sup>2</sup>)<sub>2</sub>, -S(O)<sub>2</sub>-N(R<sup>2</sup>)<sub>2</sub>, -N(R<sup>2</sup>)-C(O)-R<sup>2</sup>, -N(R<sup>2</sup>)-C(O)O-R<sup>2</sup>, -C(O)-R<sup>2</sup>, -S(O)<sub>n</sub>-R<sup>2</sup>, -OCF<sub>3</sub>, -S(O)<sub>n</sub>-Q, methylenedioxy, -N(R<sup>2</sup>)-S(O)<sub>2</sub>(R<sup>2</sup>), halo, -CF<sub>3</sub>, -NO<sub>2</sub>, Q, -OQ, -OR<sup>7</sup>, -SR<sup>7</sup>, -R<sup>7</sup>, -N(R<sup>2</sup>)(R<sup>7</sup>) or -N(R<sup>7</sup>)<sub>2</sub>;

each R<sup>2</sup> is independently selected from H, or C<sub>1</sub>-C<sub>4</sub> alkyl optionally substituted with a 3-7 membered saturated, partially saturated or unsaturated carbocyclic ring system; or a 5-7 membered saturated, partially saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from O, N, S, S(O)<sub>n</sub> or N(R<sup>33</sup>); wherein any of said ring systems or N(R<sup>33</sup>) is optionally substituted with 1 to 4 substituents independently selected from -X'-Y', -O-arylalkyl, -S-arylalkyl, -N(Y')<sub>2</sub>, -N(H)-arylalkyl, -N(C<sub>1</sub>-C<sub>4</sub> alkyl)-arylalkyl, oxo, -O-(C<sub>1</sub>-C<sub>4</sub> alkyl), OH, C<sub>1</sub>-C<sub>4</sub> alkyl, -SO<sub>2</sub>H, -SO<sub>2</sub>-(C<sub>1</sub>-C<sub>4</sub> alkyl), -SO<sub>2</sub>-NH<sub>2</sub>, -SO<sub>2</sub>-NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -SO<sub>2</sub>-N(C<sub>1</sub>-C<sub>4</sub> alkyl)<sub>2</sub>, -NH<sub>2</sub>, -NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -N(C<sub>1</sub>-C<sub>4</sub> alkyl)<sub>2</sub>, -NH-C(O)H, -N(C<sub>1</sub>-C<sub>4</sub> alkyl)-C(O)H, -NH-C(O)-C<sub>1</sub>-C<sub>4</sub> alkyl, -C<sub>1</sub>-C<sub>4</sub> alkyl-OH, -OH, -CN, -C(O)OH, -C(O)O-C<sub>1</sub>-C<sub>4</sub> alkyl, -C(O)-NH<sub>2</sub>, -C(O)-NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -C(O)-N(C<sub>1</sub>-C<sub>4</sub> alkyl)<sub>2</sub>, halo or -CF<sub>3</sub>;

Appln. No. 10/691,333  
Reply dated July 25, 2006  
In response to Office Action dated March 27, 2006

X' is -O-, -S-, -NH-, -NHC(O)-, -NHC(O)O-, -NHSO<sub>2</sub>-,  
or -N(C<sub>1</sub>-C<sub>4</sub>)alkyl-;

Y' is C<sub>1</sub>-C<sub>15</sub> alkyl, C<sub>2</sub>-C<sub>15</sub> alkenyl or alkynyl, wherein  
one to five carbon atoms in Y are optionally substituted with  
C<sub>3</sub>-C<sub>7</sub> cycloalkyl or C<sub>5</sub>-C<sub>6</sub> cycloalkenyl, C<sub>6</sub>-C<sub>14</sub> aryl or a 5-7  
membered saturated or unsaturated heterocycle, containing one  
or more heteroatoms selected from N, NH, O, S and S(O)<sub>n</sub>;

each R<sup>3</sup> is independently selected from H, Ht, C<sub>1</sub>-C<sub>6</sub>  
alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl or C<sub>5</sub>-C<sub>6</sub>  
cycloalkenyl; wherein any member of said R<sup>3</sup>, except H, is  
optionally substituted with one or more substituents selected  
from -OR<sup>2</sup>, -C(O)-N(R<sup>2</sup>)<sub>2</sub>, -S(O)<sub>n</sub>-N(R<sup>2</sup>)<sub>2</sub>, -N(R<sup>2</sup>)<sub>2</sub>, -N(R<sup>2</sup>)-C(O)O(R<sup>2</sup>),  
-N(R<sup>2</sup>)-C(O)N(R<sup>2</sup>)<sub>2</sub>, -N(R<sup>2</sup>)-C(O)-R<sup>2</sup>, Ht, -CN, -SR<sup>2</sup>, -C(O)OR<sup>2</sup>,  
N(R<sup>2</sup>)-C(O)-R<sup>2</sup>;

each R<sup>33</sup> is selected from H, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub>  
alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl or C<sub>5</sub>-C<sub>6</sub> cycloalkenyl,  
C<sub>6</sub>-C<sub>14</sub> aryl or a 5-7 membered saturated or unsaturated  
heterocycle, containing one or more heteroatoms selected from  
N, NH, O, S and S(O)<sub>n</sub>;

each n is independently 1 or 2;

G, when present, is selected from H, R<sup>7</sup> or C<sub>1</sub>-C<sub>4</sub>  
alkyl, or, when G is C<sub>1</sub>-C<sub>4</sub> alkyl, G and R<sup>7</sup> are bound to one  
another either directly or through a C<sub>1</sub>-C<sub>3</sub> linker to form a  
heterocyclic ring; or

Appln. No. 10/691,333  
Reply dated July 25, 2006  
In response to Office Action dated March 27, 2006

when G is not present (i.e., when x in  $(G)_x$  is 0), then the nitrogen to which G is attached is bound directly to the  $R^7$  group in  $-OR^7$  with the concomitant displacement of one -ZM group from  $R^7$ ;

D is selected from  $C_1$ - $C_6$  alkyl which is substituted with Q, which is optionally substituted with one or more groups selected from  $C_3$ - $C_6$  cycloalkyl,  $-R^3$ ,  $-O-Q$  or Q;  $C_2$ - $C_4$  alkenyl which is substituted with Q, which is optionally substituted with one or more groups selected from  $-OR^2$ ,  $-S-Ht$ ,  $-R^3$ ,  $-O-Q$  or Q;  $C_3$ - $C_6$  cycloalkyl, which is optionally substituted with or fused to Q; or  $C_5$ - $C_6$  cycloalkenyl, which is optionally substituted with or fused to Q;

each Q is independently selected from a 3-7 membered saturated, partially saturated or unsaturated carbocyclic ring system; or a 5-7 membered saturated, partially saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from O, N, S,  $S(O)_n$  or  $N(R^2)$ ; wherein Q contains one substituent selected from  $-OR^2$ ,  $-OR^8$ ,  $-O$ -arylalkyl,  $-SR^8$ ,  $-S$ -arylalkyl,  $-N(R^2)R^8$ ,  $-N(R^2)$ -arylalkyl and may be optionally substituted with one or more additional substituents independently selected from oxo,  $-OR^8$ ,  $-O$ -arylalkyl  $-SR^8$ ,  $-S$ -arylalkyl,  $-N(R^2)R^8$ ,  $-N(R^2)$ -arylalkyl,  $-OR^2$ ,  $-R^2$ ,  $-SO_2R^2$ ,  $-SO_2-N(R^2)_2$ ,  $-N(R^2)_2$ ,  $-N(R^2)-C(O)-R^2$ ,  $-OH$ ,  $(C_1-C_4)-OH$ ,  $-CN$ ,  $-CO_2R^2$ ,  $-C(O)-N(R^2)_2$ , halo or  $-CF_3$ ;

Appln. No. 10/691,333  
Reply dated July 25, 2006  
In response to Office Action dated March 27, 2006

each  $R^8$  is independently selected from Ht,  $-C_1-C_{15}$  branched or straight chain alkyl, alkenyl or alkynyl wherein one to five carbon atoms in said alkyl, alkenyl or alkynyl are independently replaced by W, or wherein one to five carbon atoms in said alkyl, alkenyl or alkynyl are substituted with Ht; and wherein  $R^8$  is additionally and optionally substituted with one or more groups independently selected from  $-OH$ ,  $-S(C_1-C_6 \text{ alkyl})$ ,  $-CN$ ,  $-CF_3$ ,  $-N(R^2)_2$ , halo,  $-C_1-C_4$ -alkyl,  $-C_1-C_4$ -alkoxy;  $-Ht$ ;  $-O-Ht$ ;  $-NR^2-CO-N(R^2)_2$ ;  $-CO-N(R^2)_2$ ;  $-R^1-C_2-C_6$  alkenyl, which is optionally substituted with one or more groups independently selected from hydroxy,  $C_1-C_4$  alkoxy, Ht,  $-O-Ht$ ,  $-NR^2-CO-N(R^2)_2$  or  $-CO-N(R^2)_2$ ; or  $R^7$ ;

wherein W is  $-O-$ ,  $-NR^2-$ ,  $-S-$ ,  $-C(O)-$ ,  $-C(S)-$ ,  $-C(=NR^2)-$ ,  $-S(O)_2-$ ,  $-NR^2-S(O)_2-$ ,  $-S(O)_2-NR^2-$ ,  $-NR^2-C(O)O-$ ,  $-O-C(O)NR^2-$ ,  $-NR^2-C(O)NR^2-$ ,  $-NR^2-C(S)NR^2-$ ,  $-CONR^2$ ,  $-NR^2C(O)-$ ,  $-C(S)NR^2$ ,  $-NR^2C(S)-$ ,  $-NR^2-C(=N-CN)-NR^2-$ ,  $-NR^2C(=N-CN)O-$  or  $-C(O)O-$ ;

$D'$  is selected from  $C_1-C_{15}$  alkyl,  $C_1-C_{15}$  alkoxy,  $C_2-C_{15}$  alkenyl,  $C_2-C_{15}$  alkenyloxy,  $C_2-C_{15}$  alkynyl, or  $C_2-C_{15}$  alkynyloxy, wherein  $D'$  optionally comprises one or more substituents independently selected from Ht, oxo, halo,  $-CF_3$ ,  $-OCF_3$ ,  $-NO_2$ , azido,  $-SH$ ,  $-SR^3$ ,  $-N(R^3)-N(R^3)_2$ ,  $-O-N(R^3)_2$ ,  $-(R^3)N-O-(R^3)$ ,  $-N(R^3)_2$ ,  $-CN$ ,  $-CO_2R^3$ ,  $-C(O)-N(R^3)_2$ ,  $-S(O)_n-N(R^3)_2$ ,  $-N(R^3)-C(O)-R^3$ ,  $-N(R^3)-C(O)-N(R^3)_2$ ,  $-C(O)-R^3$ ,  $-S(O)_n-R^3$ ,  $-N(R^3)-S(O)_n(R^3)$ ,  $-N(R^3)-S(O)_n-N(R^3)_2$ ,  $-S-NR^3-C(O)R^3$ ,  $-C(S)N(R^3)_2$ ,  $-C(S)R^3$ ,

$-\text{NR}^3-\text{C}(\text{O})\text{OR}^3$ ,  $-\text{O}-\text{C}(\text{O})\text{OR}^3$ ,  $-\text{O}-\text{C}(\text{O})\text{N}(\text{R}^3)_2$ ,  $-\text{NR}^3-\text{C}(\text{S})\text{R}^3$ ,  $=\text{N}-\text{OH}$ ,  
 $=\text{N}-\text{OR}^3$ ,  $=\text{N}-\text{N}(\text{R}^3)_2$ ,  $=\text{NR}^3$ ,  $=\text{NNR}^3\text{C}(\text{O})\text{N}(\text{R}^3)_2$ ,  $=\text{NNR}^3\text{C}(\text{O})\text{OR}^3$ ,  
 $=\text{NNR}^3\text{S}(\text{O})_n-\text{N}(\text{R}^3)_2$ ,  $-\text{NR}^3-\text{C}(\text{S})\text{OR}^3$ ,  $-\text{NR}^3-\text{C}(\text{S})\text{N}(\text{R}^3)_2$ ,  
 $-\text{NR}^3-\text{C}[=\text{N}(\text{R}^3)]-\text{N}(\text{R}^3)_2$ ,  $-\text{N}(\text{R}^3)-\text{C}[=\text{N}-\text{NO}_2]-\text{N}(\text{R}^3)_2$ ,  
 $-\text{N}(\text{R}^3)-\text{C}[=\text{N}-\text{NO}_2]-\text{OR}^3$ ,  $-\text{OC}(\text{O})\text{R}^3$ ,  $-\text{OC}(\text{S})\text{R}^3$ ,  $-\text{OC}(\text{O})\text{N}(\text{R}^3)_2$ ,  
 $-\text{C}(\text{O})\text{N}(\text{R}^3)-\text{N}(\text{R}^3)_2$ ,  $-\text{N}(\text{R}^3)-\text{N}(\text{R}^3)\text{C}(\text{O})\text{R}^3$ ,  $-\text{N}(\text{R}^3)-\text{OC}(\text{O})\text{R}^3$ ,  
 $-\text{N}(\text{R}^3)-\text{OC}(\text{O})\text{R}^3$ ,  $-\text{N}(\text{R}^3)-\text{OC}(\text{O})\text{R}^3$ ,  $-\text{OC}(\text{S})\text{N}(\text{R}^3)_2$ ,  $-\text{OC}(\text{S})\text{N}(\text{R}^3)(\text{R}^3)$ , or  
 $-\text{PO}_3-\text{R}^3$ ;

E is selected from Ht; O-Ht; Ht-Ht; Ht fused with Ht;  $-\text{O}-\text{R}^3$ ;  $-\text{N}(\text{R}^2)(\text{R}^3)$ ;  $-\text{N}(\text{R}^2)-\text{Ht}$ ;  $\text{C}_1-\text{C}_6$  alkyl, which is optionally substituted with one or more groups selected from  $\text{R}^4$  or Ht;  $\text{C}_2-\text{C}_6$  alkenyl, which is optionally substituted with one or more groups selected from  $\text{R}^4$  or Ht;  $\text{C}_3-\text{C}_6$  saturated carbocycle, which is optionally substituted with one or more groups selected from  $\text{R}^4$  or Ht; or  $\text{C}_5-\text{C}_6$  unsaturated carbocycle, which is optionally substituted with one or more groups selected from  $\text{R}^4$  or Ht;


each  $\text{R}^4$  is independently selected from  $-\text{R}^2$ ,  $-\text{OR}^2$ ,  $-\text{OR}^3$ ,  $-\text{SR}^2$ ,  $-\text{SOR}^2$ ,  $-\text{SO}_2\text{R}^2$ ,  $-\text{CO}_2\text{R}^2$ ,  $-\text{OC}(\text{O})-\text{R}^2$ ,  $-\text{C}(\text{O})-\text{N}(\text{R}^2)_2$ ,  $-\text{C}(\text{O})-\text{NR}^2(\text{OR}^2)$ ,  $-\text{S}(\text{O})_2-\text{N}(\text{R}^2)_2$ , halo,  $-\text{NR}^2-\text{C}(\text{O})-\text{R}^2$ ,  $-\text{NR}^2-\text{OR}^2$ ,  $-\text{N}(\text{R}^2)_2$  or  $-\text{CN}$ ;

each  $\text{R}^7$  is independently selected from hydrogen,

Appln. No. 10/691,333

Reply dated July 25, 2006

In response to Office Action dated March 27, 2006



wherein each M is independently selected

from H, Li, Na, K, Mg, Ca, Ba,  $\text{---N(R}^2\text{)}_4$ ,  $\text{C}_1\text{---C}_{12}\text{---alkyl}$ ,  $\text{C}_2\text{---C}_{12}\text{---alkenyl}$ , or  $\text{---R}^6$ ; wherein 1 to 4  $\text{---CH}_2$  radicals of the alkyl or alkenyl group, other than the  $\text{---CH}_2$  that is bound to Z, is optionally replaced by a heteroatom group selected from O, S,  $\text{S(O)}$ ,  $\text{S(O)}_2$ , or  $\text{N(R}^2\text{)}$ ; and wherein any hydrogen in said alkyl, alkenyl or  $\text{R}^6$  is optionally replaced with a substituent selected from oxo,  $\text{---C}_1\text{---C}_4$  alkyl,  $\text{---N(R}^2\text{)}_2$ ,  $\text{---N(R}^2\text{)}_3$ ,  $\text{---OH}$ ,  $\text{---O---(C}_1\text{---C}_4\text{ alkyl)}$ ,  $\text{---CN}$ ,  $\text{---C(O)OR}^2$ ,  $\text{---C(O)---N(R}^2\text{)}_2$ ,  $\text{S(O)}_2\text{---N(R}^2\text{)}_2$ ,  $\text{---N(R}^2\text{)---C(O)---R}_2$ ,  $\text{C(O)R}^2$ ,  $\text{---S(O)}_n\text{---R}^2$ ,  $\text{---OCF}_3$ ,  $\text{---S(O)}_n\text{---R}^6$ ,  $\text{---N(R}^2\text{)---S(O)}_2\text{(R}^2\text{)}$ , halo,  $\text{---CF}_3$ , or  $\text{---NO}_2$ ;

$\text{M}'$  is H,  $\text{C}_1\text{---C}_{12}\text{---alkyl}$ ,  $\text{C}_2\text{---C}_{12}\text{---alkenyl}$ , or  $\text{---R}^6$ ; wherein 1 to 4  $\text{---CH}_2$  radicals of the alkyl or alkenyl group is optionally replaced by a heteroatom group selected from O, S,  $\text{S(O)}$ ,  $\text{S(O)}_2$ , or  $\text{N(R}^2\text{)}$ ; and wherein any hydrogen in said alkyl, alkenyl or  $\text{R}^6$  is optionally replaced with a substituent selected from oxo,  $\text{---OR}^2$ ,  $\text{---C}_1\text{---C}_4$  alkyl,  $\text{---N(R}^2\text{)}_2$ ,  $\text{N(R}^2\text{)}_3$ ,  $\text{---OH}$ ,  $\text{---O---(C}_1\text{---C}_4\text{ alkyl)}$ ,  $\text{---CN}$ ,  $\text{---C(O)OR}^2$ ,  $\text{---C(O)---N(R}^2\text{)}_2$ ,  $\text{---S(O)}_2\text{---N(R}^2\text{)}_2$ ,  $\text{---N(R}^2\text{)---C(O)---R}_2$ ,  $\text{---C(O)R}^2$ ,  $\text{---S(O)}_n\text{---R}^2$ ,  $\text{---OCF}_3$ ,  $\text{---S(O)}_n\text{---R}^6$ ,  $\text{---N(R}^2\text{)---S(O)}_2\text{(R}^2\text{)}$ , halo,  $\text{---CF}_3$ , or  $\text{---NO}_2$ ;

x is 0 or 1;

Z is O, S,  $\text{N(R}^2\text{)}_2$ , or, when M is not present, H;

Appln. No. 10/691,333  
Reply dated July 25, 2006  
In response to Office Action dated March 27, 2006

Y is P or S;

X is O or S; and

$R^9$  is  $C(R^2)_2$ , O or  $N(R^2)$ ; and wherein when Y is S, Z is not S; and

$R^6$  is a 5-6 membered saturated, partially saturated or unsaturated carbocyclic or heterocyclic ring system, or an 8-10 membered saturated, partially saturated or unsaturated bicyclic ring system; wherein any of said heterocyclic ring systems contains one or more heteroatoms selected from O, N, S,  $S(O)_n$  or  $N(R^2)$ ; and wherein any of said ring systems optionally contains 1 to 4 substituents independently selected from -OH, - $C_1$ - $C_4$  alkyl, -O-( $C_1$ - $C_4$  alkyl) or -O-C(O)-( $C_1$ - $C_4$  alkyl).

2. (Original) The compound according to claim 1, wherein  $R^8$  is - $C_1$ - $C_4$ -branched or straight chain alkyl, wherein one to two carbon atoms in said alkyl are independently replaced by W, wherein  $R^8$  is additionally and optionally substituted with one or more groups independently selected from -OH; - $C_1$ - $C_4$ -alkoxy; -Ht; -O-Ht; - $NR^2$ -CO- $N(R^2)_2$ ; -CO- $N(R^2)_2$ ; - $R^1$ - $C_2$ - $C_6$  alkenyl, which is optionally substituted with one or more groups independently selected from hydroxy,  $C_1$ - $C_4$  alkoxy, Ht, -O-Ht, - $NR^2$ -CO- $N(R^2)_2$  or -CO- $N(R^2)_2$ ; or  $R^7$ ;

wherein W is -O-, - $NR^2$ -, - $NR^2$ -S(O) $_2$ -, - $NR^2$ -C(O)O-,



Appln. No. 10/691,333

Reply dated July 25, 2006

In response to Office Action dated March 27, 2006

$-O-C(O)NR^2-$ ,  $-NR^2-C(O)NR^2-$ ,  $-NR^2-C(S)NR^2-$ ,  $-NR^2C(O)-$ ,  $-C(=NR^2)-$ ,  
 $-C(O)NR^2-$ ,  $-NR^2-C(=N-CN)-NR^2-$ ,  $-NR^2C(=N-CN)O-$  or  $-C(O)O-$ ; and  
wherein Ht,  $R^1$ ,  $R^2$  and  $R^7$  are as defined in claim 1.

3. (Previously presented) The compound according to claim 1, wherein  $R^8$  is a  $-C_1-C_4$ -branched or straight alkyl chain, wherein one to two carbon atoms are substituted with Ht;


wherein Ht is  $C_{6-14}$  aryl or a 5-7 membered saturated or unsaturated heterocycle, containing one or more heteroatoms selected from N,  $N(R^2)$ , O, S and  $S(O)_n$ , wherein any member of Ht is optionally substituted with one or more substituents independently selected from oxo,  $-OR^2$ ,  $SR^2$ ,  $-R^2$ ,  $-N(R^2)(R^2)$ ,  $-R^2-OH$ ,  $-CN$ ,  $-CO_2R^2$ ,  $-C(O)-N(R^2)_2$ ,  $-S(O)_2-N(R^2)_2$ ,  $-N(R^2)-C(O)-R^2$ ,  $-N(R^2)-C(O)O-R^2$ ,  $-C(O)-R^2$ ,  $-S(O)_n-R^2$ ,  $-OCF_3$ ,  $-S(O)_n-Q$ , methylenedioxy,  $-N(R^2)-S(O)_2(R^2)$ , halo,  $-CF_3$ ,  $-NO_2$ , Q,  $-OQ$ ,  $-OR^7$ ,  $-SR^7$ ,  $-R^7$ ,  $-N(R^2)(R^7)$  or  $-N(R^7)_2$ .

4. (Currently amended) The compound according to claim 1, wherein  $R^8$  is selected from:

Appln. No. 10/691,333

Reply dated July 25, 2006


In response to Office Action dated March 27, 2006




Appln. No. 10/691,333

Reply dated July 25, 2006


In response to Office Action dated March 27, 2006



5. (Original) The compound according to claim 1,  
wherein at least one R<sup>7</sup> is selected from:




In response to Office Action dated March 27, 2006



Page 13 of 42

7. (Currently amended) The compound according to claim 1, wherein:


D' is  $-\text{CH}_2-\text{R}''$ , wherein R'' is selected from:  
 isobutyl,;



wherein m is 0 to 3.

8. (Previously presented) The compound according to claim 1, wherein:

E is selected from:




9. (Currently amended) A compound having the

Appln. No. 10/691,333

Reply dated July 25, 2006

In response to Office Action dated March 27, 2006

formula (II):



and pharmaceutically acceptable salts thereof;








wherein:

A is selected from R'-C(O)-, wherein R' is ~~selected~~  
~~from R<sup>±</sup>-C<sub>1</sub>-C<sub>6</sub>-alkyl,~~






Appln. No. 10/691,333

Reply dated July 25, 2006


In response to Office Action dated March 27, 2006



or



or



[[.]]

[[,]]

or

;

each  $R^1$  is independently selected from  $-\text{C}(\text{O})-$ ,  
 $-\text{S}(\text{O})_2-$ ,  $-\text{C}(\text{O})-\text{C}(\text{O})-$ ,  $-\text{O}-\text{C}(\text{O})-$ ,  $-\text{O}-\text{S}(\text{O})_2-$ ,  $-\text{NR}^2-$ ,  $-\text{NR}^2-\text{S}(\text{O})_2-$ ,  
 $-\text{NR}^2-\text{C}(\text{O})-$  or  $-\text{NR}^2-\text{C}(\text{O})-\text{C}(\text{O})-$ ;

each Ht is independently selected from  $\text{C}_3$ - $\text{C}_7$   
cycloalkyl;  $\text{C}_5$ - $\text{C}_7$  cycloalkenyl;  $\text{C}_6$ - $\text{C}_{14}$  aryl; or a 5-7 membered

saturated or unsaturated heterocycle, containing one or more heteroatoms selected from N, N(R<sup>2</sup>), O, S and S(O)<sub>n</sub>; wherein said aryl or said heterocycle is optionally fused to Q; and wherein any member of said Ht is optionally substituted with one or more substituents independently selected from oxo, -OR<sup>2</sup>, SR<sup>2</sup>, -R<sup>2</sup>, -N(R<sup>2</sup>)(R<sup>2</sup>), -R<sup>2</sup>-OH, -CN, -CO<sub>2</sub>R<sup>2</sup>, -C(O)-N(R<sup>2</sup>)<sub>2</sub>, -S(O)<sub>2</sub>-N(R<sup>2</sup>)<sub>2</sub>, -N(R<sup>2</sup>)-C(O)-R<sup>2</sup>, -N(R<sup>2</sup>)-C(O)O-R<sup>2</sup>, -C(O)-R<sup>2</sup>, -S(O)<sub>n</sub>-R<sup>2</sup>, -OCF<sub>3</sub>, -S(O)<sub>n</sub>-Q, methylenedioxy, -N(R<sup>2</sup>)-S(O)<sub>2</sub>(R<sup>2</sup>), halo, -CF<sub>3</sub>, -NO<sub>2</sub>, Q, -OQ, -OR<sup>7</sup>, -SR<sup>7</sup>, -R<sup>7</sup>, -N(R<sup>2</sup>)(R<sup>7</sup>) or -N(R<sup>7</sup>)<sub>2</sub>;

each R<sup>2</sup> is independently selected from H, or C<sub>1</sub>-C<sub>4</sub> alkyl optionally substituted with a 3-7 membered saturated, partially saturated or unsaturated carbocyclic ring system; or a 5-7 membered saturated, partially saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from O, N, S, S(O)<sub>n</sub> or N(R<sup>33</sup>); wherein any of said ring systems or N(R<sup>33</sup>) is optionally substituted with 1 to 4 substituents independently selected from -X'-Y', -O-arylalkyl, -S-arylalkyl, -N(Y')<sub>2</sub>, -N(H)-arylalkyl, -N(C<sub>1</sub>-C<sub>4</sub> alkyl)-arylalkyl, oxo, -O-(C<sub>1</sub>-C<sub>4</sub> alkyl), OH, C<sub>1</sub>-C<sub>4</sub> alkyl, -SO<sub>2</sub>H, -SO<sub>2</sub>-(C<sub>1</sub>-C<sub>4</sub> alkyl), -SO<sub>2</sub>-NH<sub>2</sub>, -SO<sub>2</sub>-NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -SO<sub>2</sub>-N(C<sub>1</sub>-C<sub>4</sub> alkyl)<sub>2</sub>, -NH<sub>2</sub>, -NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -N(C<sub>1</sub>-C<sub>4</sub> alkyl)<sub>2</sub>, -NH-C(O)H, -N(C<sub>1</sub>-C<sub>4</sub> alkyl)-C(O)H, -NH-C(O)-C<sub>1</sub>-C<sub>4</sub> alkyl, -C<sub>1</sub>-C<sub>4</sub> alkyl-OH, -OH, -CN, -C(O)OH, -C(O)O-C<sub>1</sub>-C<sub>4</sub> alkyl, -C(O)-NH<sub>2</sub>, -C(O)-NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -C(O)-N(C<sub>1</sub>-C<sub>4</sub> alkyl)<sub>2</sub>, halo or -CF<sub>3</sub>;



Appln. No. 10/691,333  
Reply dated July 25, 2006  
In response to Office Action dated March 27, 2006

X' is -O-, -S-, -NH-, -NHC(O)-, -NHC(O)O-, -NHSO<sub>2</sub>-,  
or -N(C<sub>1</sub>-C<sub>4</sub>)alkyl-;

Y' is C<sub>1</sub>-C<sub>15</sub> alkyl, C<sub>2</sub>-C<sub>15</sub> alkenyl or alkynyl, wherein  
one to five carbon atoms in Y are optionally substituted with  
C<sub>3</sub>-C<sub>7</sub> cycloalkyl or C<sub>5</sub>-C<sub>6</sub> cycloalkenyl, C<sub>6</sub>-C<sub>14</sub> aryl or a 5-7  
membered saturated or unsaturated heterocycle, containing one  
or more heteroatoms selected from N, NH, O, S and S(O)<sub>n</sub>;

each R<sup>3</sup> is independently selected from H, Ht, C<sub>1</sub>-C<sub>6</sub>  
alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl or C<sub>5</sub>-C<sub>6</sub>  
cycloalkenyl; wherein any member of said R<sup>3</sup>, except H, is  
optionally substituted with one or more substituents selected  
from -OR<sup>2</sup>, -C(O)-N(R<sup>2</sup>)<sub>2</sub>, -S(O)<sub>n</sub>-N(R<sup>2</sup>)<sub>2</sub>, -N(R<sup>2</sup>)<sub>2</sub>, -N(R<sup>2</sup>)-C(O)O(R<sup>2</sup>),  
-N(R<sup>2</sup>)-C(O)N(R<sup>2</sup>)<sub>2</sub>, -N(R<sup>2</sup>)-C(O)-R<sup>2</sup>, Ht, -CN, -SR<sup>2</sup>, -C(O)OR<sup>2</sup>,  
N(R<sup>2</sup>)-C(O)-R<sup>2</sup>;

each R<sup>33</sup> is selected from H, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub>  
alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl or C<sub>5</sub>-C<sub>6</sub> cycloalkenyl,  
C<sub>6</sub>-C<sub>14</sub> aryl or a 5-7 membered saturated or unsaturated  
heterocycle, containing one or more heteroatoms selected from  
N, NH, O, S and S(O)<sub>n</sub>;

each n is independently 1 or 2;

each Q is independently selected from a 3-7 membered  
saturated, partially saturated or unsaturated carbocyclic ring  
system; or a 5-7 membered saturated, partially saturated or  
unsaturated heterocyclic ring containing one or more

heteroatoms selected from O, N, S, S(O)<sub>n</sub> or N(R<sup>2</sup>); wherein Q contains one substituent selected from -OR<sup>2</sup>, -OR<sup>8</sup>, -O-arylalkyl, -SR<sup>8</sup>, -S-arylalkyl, -N(R<sup>2</sup>)R<sup>8</sup>, -N(R<sup>2</sup>)-arylalkyl and may be optionally substituted with one or more additional substituents independently selected from oxo, -OR<sup>8</sup>, -O-arylalkyl -SR<sup>8</sup>, -S-arylalkyl, -N(R<sup>2</sup>)R<sup>8</sup>, -N(R<sup>2</sup>)-arylalkyl, -OR<sup>2</sup>, -R<sup>2</sup>, -SO<sub>2</sub>R<sup>2</sup>, -SO<sub>2</sub>-N(R<sup>2</sup>)<sub>2</sub>, -N(R<sup>2</sup>)<sub>2</sub>, -N(R<sup>2</sup>)-C(O)-R<sup>2</sup>, -OH, (C<sub>1</sub>-C<sub>4</sub>)-OH, -CN, -CO<sub>2</sub>R<sup>2</sup>, -C(O)-N(R<sup>2</sup>)<sub>2</sub>, halo or -CF<sub>3</sub>;

each R<sup>8</sup> is independently selected from Ht, -C<sub>1</sub>-C<sub>15</sub> branched or straight chain alkyl, alkenyl or alkynyl wherein one to five carbon atoms in said alkyl, alkenyl or alkynyl are independently replaced by W, or wherein one to five carbon atoms in said alkyl, alkenyl or alkynyl are substituted with Ht; and wherein R<sup>8</sup> is additionally and optionally substituted with one or more groups independently selected from -OH, -S(C<sub>1</sub>-C<sub>6</sub> alkyl), -CN, -CF<sub>3</sub>, -N(R<sup>2</sup>)<sub>2</sub>, halo, -C<sub>1</sub>-C<sub>4</sub>-alkyl, -C<sub>1</sub>-C<sub>4</sub>-alkoxy; -Ht; -O-Ht; -NR<sup>2</sup>-CO-N(R<sup>2</sup>)<sub>2</sub>; -CO-N(R<sup>2</sup>)<sub>2</sub>; -R<sup>1</sup>-C<sub>2</sub>-C<sub>6</sub> alkenyl, which is optionally substituted with one or more groups independently selected from hydroxy, C<sub>1</sub>-C<sub>4</sub> alkoxy, Ht, -O-Ht, -NR<sup>2</sup>-CO-N(R<sup>2</sup>)<sub>2</sub> or -CO-N(R<sup>2</sup>)<sub>2</sub>; or R<sup>7</sup>;

wherein W is -O-, -NR<sup>2</sup>-, -S-, -C(O)-, -C(S)-, -C(=NR<sup>2</sup>)-, -S(O)<sub>2</sub>-, -NR<sup>2</sup>-S(O)<sub>2</sub>-, -S(O)<sub>2</sub>-NR<sup>2</sup>-, -NR<sup>2</sup>-C(O)O-, -O-C(O)NR<sup>2</sup>-, -NR<sup>2</sup>-C(O)NR<sup>2</sup>-, -NR<sup>2</sup>-C(S)NR<sup>2</sup>-, -CONR<sup>2</sup>, -NR<sup>2</sup>C(O)-, -C(S)NR<sup>2</sup>, -NR<sup>2</sup>C(S)-, -NR<sup>2</sup>-C(=N-CN)-NR<sup>2</sup>-, -NR<sup>2</sup>C(=N-CN)O- or -C(O)O-;

Appln. No. 10/691,333  
Reply dated July 25, 2006  
In response to Office Action dated March 27, 2006


D' is selected from C<sub>1</sub>-C<sub>15</sub> alkyl, C<sub>1</sub>-C<sub>15</sub> alkoxy, C<sub>2</sub>-C<sub>15</sub> alkenyl, C<sub>2</sub>-C<sub>15</sub> alkenyloxy, C<sub>2</sub>-C<sub>15</sub> alkynyl, or C<sub>2</sub>-C<sub>15</sub> alkynyloxy, wherein D' optionally comprises one or more substituents independently selected from Ht, oxo, halo, -CF<sub>3</sub>, -OCF<sub>3</sub>, -NO<sub>2</sub>, azido, -SH, -SR<sup>3</sup>, -N(R<sup>3</sup>)-N(R<sup>3</sup>)<sub>2</sub>, -O-N(R<sup>3</sup>)<sub>2</sub>, -(R<sup>3</sup>)N-O-(R<sup>3</sup>), -N(R<sup>3</sup>)<sub>2</sub>, -CN, -CO<sub>2</sub>R<sup>3</sup>, -C(O)-N(R<sup>3</sup>)<sub>2</sub>, -S(O)<sub>n</sub>-N(R<sup>3</sup>)<sub>2</sub>, -N(R<sup>3</sup>)-C(O)-R<sup>3</sup>, -N(R<sup>3</sup>)-C(O)-N(R<sup>3</sup>)<sub>2</sub>, -C(O)-R<sup>3</sup>, -S(O)<sub>n</sub>-R<sup>3</sup>, -N(R<sup>3</sup>)-S(O)<sub>n</sub>(R<sup>3</sup>), -N(R<sup>3</sup>)-S(O)<sub>n</sub>-N(R<sup>3</sup>)<sub>2</sub>, -S-NR<sup>3</sup>-C(O)R<sup>3</sup>, -C(S)N(R<sup>3</sup>)<sub>2</sub>, -C(S)R<sup>3</sup>, -NR<sup>3</sup>-C(O)OR<sup>3</sup>, -O-C(O)OR<sup>3</sup>, -O-C(O)N(R<sup>3</sup>)<sub>2</sub>, -NR<sup>3</sup>-C(S)R<sup>3</sup>, =N-OH, =N-OR<sup>3</sup>, =N-N(R<sup>3</sup>)<sub>2</sub>, =NR<sup>3</sup>, =NNR<sup>3</sup>C(O)N(R<sup>3</sup>)<sub>2</sub>, =NNR<sup>3</sup>C(O)OR<sup>3</sup>, =NNR<sup>3</sup>S(O)<sub>n</sub>-N(R<sup>3</sup>)<sub>2</sub>, -NR<sup>3</sup>-C(S)OR<sup>3</sup>, -NR<sup>3</sup>-C(S)N(R<sup>3</sup>)<sub>2</sub>, -NR<sup>3</sup>-C[=N(R<sup>3</sup>)]-N(R<sup>3</sup>)<sub>2</sub>, -N(R<sup>3</sup>)-C[=N-NO<sub>2</sub>]-N(R<sup>3</sup>)<sub>2</sub>, -N(R<sup>3</sup>)-C[=N-NO<sub>2</sub>]-OR<sup>3</sup>, -OC(O)R<sup>3</sup>, -OC(S)R<sup>3</sup>, -OC(O)N(R<sup>3</sup>)<sub>2</sub>, -C(O)N(R<sup>3</sup>)-N(R<sup>3</sup>)<sub>2</sub>, -N(R<sup>3</sup>)-N(R<sup>3</sup>)C(O)R<sup>3</sup>, -N(R<sup>3</sup>)-OC(O)R<sup>3</sup>, -N(R<sup>3</sup>)-OC(O)R<sup>3</sup>, -N(R<sup>3</sup>)-OC(O)R<sup>3</sup>, -OC(S)N(R<sup>3</sup>)<sub>2</sub>, -OC(S)N(R<sup>3</sup>)(R<sup>3</sup>), or -PO<sub>3</sub>-R<sup>3</sup>;

E is selected from Ht; O-Ht; Ht-Ht; Ht fused with Ht; -O-R<sup>3</sup>; -N(R<sup>2</sup>)(R<sup>3</sup>); -N(R<sup>2</sup>)-Ht; C<sub>1</sub>-C<sub>6</sub> alkyl, which is optionally substituted with one or more groups selected from R<sup>4</sup> or Ht; C<sub>2</sub>-C<sub>6</sub> alkenyl, which is optionally substituted with one or more groups selected from R<sup>4</sup> or Ht; C<sub>3</sub>-C<sub>6</sub> saturated carbocycle, which is optionally substituted with one or more groups selected from R<sup>4</sup> or Ht; or C<sub>5</sub>-C<sub>6</sub> unsaturated carbocycle, which is optionally substituted with one or more groups

selected from  $R^4$  or Ht;

each  $R^4$  is independently selected from  $-R^2$ ,  $-OR^2$ ,  $-OR^3$ ,  $-SR^2$ ,  $-SOR^2$ ,  $-SO_2R^2$ ,  $-CO_2R^2$ ,  $-OC(O)-R^2$ ,  $-C(O)-N(R^2)_2$ ,  $-C(O)-NR^2(OR^2)$ ,  $-S(O)_2-N(R^2)_2$ , halo,  $-NR^2-C(O)-R^2$ ,  $-NR^2-OR^2$ ,  $-N(R^2)_2$  or  $-CN$ ;

each  $R^7$  is independently selected from hydrogen,



wherein each M is independently selected from H, Li, Na, K, Mg, Ca, Ba,  $-N(R^2)_4$ ,  $C_1$ - $C_{12}$ -alkyl,  $C_2$ - $C_{12}$ -alkenyl, or  $-R^6$ ; wherein 1 to 4  $-\text{CH}_2$  radicals of the alkyl or alkenyl group, other than the  $-\text{CH}_2$  that is bound to Z, is optionally replaced by a heteroatom group selected from O, S,  $S(O)$ ,  $S(O)_2$ , or  $N(R^2)$ ; and wherein any hydrogen in said alkyl, alkenyl or  $R^6$  is optionally replaced with a substituent selected from oxo,  $-C_1$ - $C_4$  alkyl,  $-N(R^2)_2$ ,  $-N(R^2)_3$ ,  $-\text{OH}$ ,  $-\text{O}-(C_1-C_4 \text{ alkyl})$ ,  $-\text{CN}$ ,  $-C(O)OR^2$ ,  $-C(O)-N(R^2)_2$ ,  $S(O)_2-N(R^2)_2$ ,  $-N(R^2)-C(O)-R^2$ ,  $C(O)R^2$ ,  $-S(O)_n-R^2$ ,  $-\text{OCF}_3$ ,  $-S(O)_n-R^6$ ,  $-N(R^2)-S(O)_2(R^2)$ , halo,  $-\text{CF}_3$ , or  $-\text{NO}_2$ ;

$M'$  is H,  $C_1$ - $C_{12}$ -alkyl,  $C_2$ - $C_{12}$ -alkenyl, or  $-R^6$ ; wherein 1 to 4  $-\text{CH}_2$  radicals of the alkyl or alkenyl group is optionally replaced by a heteroatom group selected from O, S,

S(O), S(O<sub>2</sub>), or N(R<sup>2</sup>); and wherein any hydrogen in said alkyl, alkenyl or R<sup>6</sup> is optionally replaced with a substituent selected from oxo, -OR<sup>2</sup>, -C<sub>1</sub>-C<sub>4</sub> alkyl, -N(R<sup>2</sup>)<sub>2</sub>, N(R<sup>2</sup>)<sub>3</sub>, -OH, -O-(C<sub>1</sub>-C<sub>4</sub> alkyl), -CN, -C(O)OR<sup>2</sup>, -C(O)-N(R<sup>2</sup>)<sub>2</sub>, -S(O)<sub>2</sub>-N(R<sup>2</sup>)<sub>2</sub>, -N(R<sup>2</sup>)-C(O)-R<sub>2</sub>, -C(O)R<sup>2</sup>, -S(O)<sub>n</sub>-R<sup>2</sup>, -OCF<sub>3</sub>, -S(O)<sub>n</sub>-R<sup>6</sup>, -N(R<sup>2</sup>)-S(O)<sub>2</sub>(R<sup>2</sup>), halo, -CF<sub>3</sub>, or -NO<sub>2</sub>;

x is 0 or 1;

Z is O, S, N(R<sup>2</sup>)<sub>2</sub>, or, when M is not present, H;

Y is P or S;

X is O or S; and

R<sup>9</sup> is C(R<sup>2</sup>)<sub>2</sub>, O or N(R<sup>2</sup>); and wherein when Y is S, Z is not S; and


R<sup>6</sup> is a 5-6 membered saturated, partially saturated or unsaturated carbocyclic or heterocyclic ring system, or an 8-10 membered saturated, partially saturated or unsaturated bicyclic ring system; wherein any of said heterocyclic ring systems contains one or more heteroatoms selected from O, N, S, S(O)<sub>n</sub> or N(R<sup>2</sup>); and wherein any of said ring systems optionally contains 1 to 4 substituents independently selected from -OH, -C<sub>1</sub>-C<sub>4</sub> alkyl, -O-(C<sub>1</sub>-C<sub>4</sub> alkyl) or -O-C(O)-(C<sub>1</sub>-C<sub>4</sub> alkyl).

10. (Original) The compound according to claim 9, wherein R<sup>8</sup> is selected from:


Appln. No. 10/691,333

Reply dated July 25, 2006

In response to Office Action dated March 27, 2006



11. (Original) The compound according to claim 9,  
wherein R<sup>8</sup> is selected from:



12. (Original) The compound according to claim 9,

In response to Office Action dated March 27, 2006


Chemical structures of the polymers used in the study:

- (a) Poly(N-benzyl-L-glutamate)
- (b) Poly(N-(2-furyl)-L-glutamate)
- (c) Poly(N-ethyl-L-glutamate)


Appln. No. 10/691,333

Reply dated July 25, 2006

In response to Office Action dated March 27, 2006



14. (Currently amended) The compound according to claim 9, wherein R<sup>8</sup> is selected from:





Appln. No. 10/691,333  
Reply dated July 25, 2006  
In response to Office Action dated March 27, 2006

15. (Currently amended) The compound according to claim 9, wherein said compound is selected from compound numbers: ~~22, 24, 25,~~ 26, 27, 31, 33, 35, 36, 38, 41, 43, 48, 49, 51, 52, 53, 54, 55, 56, 57, 59, 60, ~~69,~~ 71, 72, 73, 74, 202, 203, 209, 213, 215, 223, 227, 231, 233, 236, 237, 239, 243, 247, 250, 260, 263, 271, 281, 289, 293, 295, 309, 317, 319, 320, 322, 334, 335, 348, 364, 367, 368, 375, 382, 383 and 396.

16. (Currently amended) The compound according to claim 15, wherein said compound is selected from compound numbers: 26, 27, 31, 33, 35, 36, 38, 41, 43, 48, 49, 51, 52, 53, 54, 55, 56, 57, 59, 60, ~~69,~~ 71, 72, 73, 74, 209, 215, 227, 233, 237, 281, 289, 295, 309, 322, 335, 364, 368, 382 and 383.

17. (Previously presented) The compound according to claim 16, wherein said compound is selected from: 54, 209, 237, 281, 295, 309, and 368.

18. (Previously presented) A composition comprising a compound according to claim 1 or 9, in an amount sufficient to inhibit an aspartyl protease; and a pharmaceutically acceptable carrier.

19. (Original) The composition according to claim 18, wherein said composition is in a pharmaceutically acceptable form for administration to a human being.

20. (Original) The composition according to claim 18, wherein said composition additionally comprises an additional anti-viral agent.

21. (Original) The composition according to claim 18, wherein said composition comprises at least one additional therapeutic agent selected from (1 alpha, 2 beta, 3 alpha)-9-[2,3-bis(hydroxymethyl)cyclobutyl]- guanine [(-)BHCG, SQ-34514]; oxetanocin-G (3,4-bis-(hydroxymethyl)-2-oxetanosyl]guanine); acyclic nucleosides, such as acyclovir, valaciclovir, famciclovir, ganciclovir or penciclovir; acyclic nucleoside phosphonates, such as (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine (HPMPC); ribonucleotide reductase inhibitors, such as 2-acetylpyridine 5-[(2-chloroanilino)thiocarbonyl) thiocarbonohydrazone, 3'-azido-3'-deoxythymidine; other 2',3'-dideoxynucleosides such as 2',3'-dideoxycytidine, 2',3'-dideoxyadenosine, 2',3'-dideoxyinosine, or 2',3'-didehydrothymidine; other aspartyl protease inhibitors, such as indinavir, ritonavir, nelfinavir, or [3S-[3R\*(1R\*, 2S\*)]]-[3[[ (4-aminophenyl)sulfonyl] (2-

Appln. No. 10/691,333  
Reply dated July 25, 2006  
In response to Office Action dated March 27, 2006

methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-  
tetrahydro-3-furanyl ester (amprenavir); oxathiolane  
nucleoside analogues, such as (-)-cis-1-(2-hydroxymethyl)-1,3-  
oxathiolane 5-yl)-cytosine (lamivudine) or cis-1-(2-  
(hydroxymethyl)-1,3-oxathiolan-5-yl)-5-fluorocytosine (FTC);  
3'-deoxy-3'-fluorothymidine; 5-chloro-2',3'-dideoxy-3'-  
fluorouridine; (-)-cis-4-[2-amino-6-(cyclopropylamino)-9H-  
purin-9-yl]-2-cyclopentene-1-methanol; ribavirin; 9-[4-  
hydroxy-2-(hydroxymethyl)but-1-yl]-guanine (H2G); tat  
inhibitors, such as 7-chloro-5-(2-pyrryl)-3H-1,4-  
benzodiazepin-2-(H)one (Ro5-3335) or 7-chloro-1,3-dihydro-5-  
(1H-pyrrol-2yl)-3H-1,4-benzodiazepin-2-amine (Ro24-7429);  
interferons, such as  $\alpha$ -interferon; renal excretion inhibitors  
such as probenecid; nucleoside transport inhibitors such as  
dipyridamole; pentoxifylline; N-acetylcysteine (NAC);  
Procysteine;  $\alpha$ -trichosanthin; phosphonoformic acid;  
immunomodulators, such as interleukin II or thymosin;  
granulocyte macrophage colony stimulating factors;  
erythropoetin; soluble CD<sub>4</sub> and genetically engineered  
derivatives thereof; non-nucleoside reverse transcriptase  
inhibitors (NNRTIs), such as nevirapine (BI-RG-587), loviride  
( $\alpha$ -APA) or delavuridine (BHAP); phosphonoformic acid; 1,4-  
dihydro-2H-3,1-benzoxazin-2-ones NNRTIs, such as (-)-6-chloro-

Appln. No. 10/691,333  
Reply dated July 25, 2006  
In response to Office Action dated March 27, 2006

4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one (L-743,726 or DMP-266); or quinoxaline NNRTIs, such as isopropyl (2S)-7-fluoro-3,4-dihydro-2-ethyl-3-oxo-1(2H)-quinoxalinecarboxylate (HBY1293).

22. (Previously presented) The composition according to claim 18, wherein said composition is in an orally available dosage form.

23. (Withdrawn) A method of treating a patient infected with a virus that depends upon an aspartyl protease for an obligatory event in its life cycle comprising the step of administering to said patient a composition according to claim 18.

24. (Withdrawn) A method of treating a patient infected with HIV-I or HIV-II comprising the step of administering to said patient a composition according to claim 18.

25. (Withdrawn) The method according to claim 23, comprising the additional step of administering to said patient an additional therapeutic agent selected from (1 alpha, 2 beta, 3 alpha)-9-[2,3-bis(hydroxymethyl)

Appln. No. 10/691,333  
Reply dated July 25, 2006  
In response to Office Action dated March 27, 2006

cyclobutyl]guanine [(-)BHCG, SQ-34514]; oxetanocin-G (3,4-bis-(hydroxymethyl)-2-oxetanosyl]guanine); acyclic nucleosides, such as acyclovir, valaciclovir, famciclovir, ganciclovir or penciclovir; acyclic nucleoside phosphonates, such as (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine (HPMPC); ribonucleotide reductase inhibitors, such as 2-acetylpyridine 5-[(2-chloroanilino)thiocarbonyl] thiocarbonohydrazone, 3'-azido-3'-deoxythymidine; other 2',3'-dideoxynucleosides such as 2',3'-dideoxycytidine, 2',3'-dideoxyadenosine, 2',3'-dideoxyinosine, or 2',3'-didehydrothymidine; other aspartyl protease inhibitors, such as indinavir, ritonavir, nelfinavir, or [3S-[3R\*(1R\*, 2S\*)]]-[3[[[4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-tetrahydro-3-furanyl ester (amprenavir); oxathiolane nucleoside analogues, such as (-)-cis-1-(2-hydroxymethyl)-1,3-oxathiolane 5-yl)-cytosine (lamivudine) or cis-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-5-fluorocytosine (FTC); 3'-deoxy-3'-fluorothymidine; 5-chloro-2',3'-dideoxy-3'-fluorouridine; (-)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; ribavirin; 9-[4-hydroxy-2-(hydroxymethyl)but-1-yl]-guanine (H2G); tat inhibitors, such as 7-chloro-5-(2-pyrrolyl)-3H-1,4-benzodiazepin-2-(H)one (Ro5-3335) or 7-chloro-1,3-dihydro-5-(1H-pyrrol-2-yl)-3H-1,4-benzodiazepin-2-amine (Ro24-7429);

Appln. No. 10/691,333  
Reply dated July 25, 2006  
In response to Office Action dated March 27, 2006

interferons, such as  $\alpha$ -interferon; renal excretion inhibitors such as probenecid; nucleoside transport inhibitors such as dipyridamole; pentoxifylline; N-acetylcysteine (NAC); Procysteine;  $\alpha$ -trichosanthin; phosphonoformic acid; immunomodulators, such as interleukin II or thymosin; granulocyte macrophage colony stimulating factors; erythropoietin; soluble CD<sub>4</sub> and genetically engineered derivatives thereof; non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as nevirapine (BI-RG-587), loviride ( $\alpha$ -APA) or delavuridine (BHAP); phosphonoformic acid; 1,4-dihydro-2H-3,1-benzoxazin-2-ones NNRTIs, such as (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one (L-743,726 or DMP-266); or quinoxaline NNRTIs, such as isopropyl (2S)-7-fluoro-3,4-dihydro-2-ethyl-3-oxo-1(2H)-quinoxalinecarboxylate (HBY1293), wherein said additional agent is administered to said patient as either a separate dosage form or as a single dosage form together with said compound.

26. (Withdrawn) A method of treating a patient diagnosed with AIDS; AIDS related complex (ARC); progressive generalized lymphadenopathy (PGL); Kaposi's sarcoma, thrombocytopenic purpura; AIDS-related neurological conditions

Appln. No. 10/691,333  
Reply dated July 25, 2006  
In response to Office Action dated March 27, 2006

such as AIDS dementia complex, multiple sclerosis or tropical paraperesis; anti-HIV antibody-positive conditions; or HIV-positive conditions, comprising the step of administering to said patient a composition according to claim 18.

27. (Withdrawn) The method according to claim 26, comprising the additional step of administering to said patient an additional therapeutic agent selected from (1 alpha, 2 beta, 3 alpha)-9-[2,3-bis(hydroxymethyl)cyclobutyl]guanine [(-)BHCG, SQ-34514]; oxetanocin-G (3,4-bis-(hydroxymethyl)-2-oxetanosyl]guanine); acyclic nucleosides, such as acyclovir, valaciclovir, famciclovir, ganciclovir or penciclovir; acyclic nucleoside phosphonates, such as (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine (HPMPC); ribonucleotide reductase inhibitors, such as 2-acetylpyridine 5-[(2-chloroanilino)thiocarbonyl] thiocarbonohydrazone, 3'azido-3'-deoxythymidine; other 2',3'-dideoxynucleosides such as 2',3'-dideoxycytidine, 2',3'-dideoxyadenosine, 2',3'-dideoxyinosine, or 2',3'-didehydrothymidine; other aspartyl protease inhibitors, such as indinavir, ritonavir, nelfinavir, or [3S-[3R\*(1R\*, 2S\*)]]-[3[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-tetrahydro-3-furanyl ester (amprenavir); oxathiolane nucleoside analogues, such as (-)-cis-1-(2-hydroxymethyl)-1,3-

Appln. No. 10/691,333  
Reply dated July 25, 2006  
In response to Office Action dated March 27, 2006

oxathiolane 5-yl)-cytosine (lamivudine) or cis-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-5-fluorocytosine (FTC); 3'-deoxy-3'-fluorothymidine; 5-chloro-2',3'-dideoxy-3'-fluorouridine; (-)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; ribavirin; 9-[4-hydroxy-2-(hydroxymethyl)but-1-yl]-guanine (H2G); tat inhibitors, such as 7-chloro-5-(2-pyrryl)-3H-1,4-benzodiazepin-2-(H)one (Ro5-3335) or 7-chloro-1,3-dihydro-5-(1H-pyrrol-2-yl)-3H-1,4-benzodiazepin-2-amine (Ro24-7429); interferons, such as  $\alpha$ -interferon; renal excretion inhibitors such as probenecid; nucleoside transport inhibitors such as dipyridamole; pentoxifylline; N-acetylcysteine (NAC); Procysteine;  $\alpha$ -trichosanthin; phosphonoformic acid; immunomodulators, such as interleukin II or thymosin; granulocyte macrophage colony stimulating factors; erythropoietin; soluble CD<sub>4</sub> and genetically engineered derivatives thereof; non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as nevirapine (BI-RG-587), loviride ( $\alpha$ -APA) or delavuridine (BHAP); phosphonoformic acid; 1,4-dihydro-2H-3,1-benzoxazin-2-ones NNRTIs, such as (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one (L-743,726 or DMP-266); or quinoxaline NNRTIs, such as isopropyl (2S)-7-fluoro-3,4-dihydro-2-ethyl-3-



Appln. No. 10/691,333  
Reply dated July 25, 2006  
In response to Office Action dated March 27, 2006

oxo-1(2H)-quinoxalinecarboxylate (HBY1293), wherein said additional agent is administered to said patient as either a separate dosage form or as a single dosage form together with said compound.

28. (Previously presented) The compound according to claim 15, wherein said compound is compound number 368.

29. (Previously presented) The composition according to claim 19, wherein said composition is in an orally available dosage form.

30. (Previously presented) The composition according to claim 20, wherein said composition is in an orally available dosage form.

31. (Previously presented) The composition according to claim 21, wherein said composition is in an orally available dosage form.

32. (Withdrawn) The method according to claim 24, comprising the additional step of administering to said patient an additional therapeutic agent selected from (1 alpha, 2 beta, 3 alpha)-9-[2,3-bis(hydroxymethyl)

Appln. No. 10/691,333  
Reply dated July 25, 2006  
In response to Office Action dated March 27, 2006

cyclobutyl]guanine [(-)BHCG, SQ-34514]; oxetanocin-G (3,4-bis-(hydroxymethyl)-2-oxetanosyl]guanine); acyclic nucleosides, such as acyclovir, valaciclovir, famciclovir, ganciclovir or penciclovir; acyclic nucleoside phosphonates, such as (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine (HPMPC); ribonucleotide reductase inhibitors, such as 2-acetylpyridine 5-[(2-chloroanilino)thiocarbonyl] thiocarbonohydrazone, 3'-azido-3'-deoxythymidine; other 2',3'-dideoxynucleosides such as 2',3'-dideoxycytidine, 2',3'-dideoxyadenosine, 2',3'-dideoxyinosine, or 2',3'-didehydrothymidine; other aspartyl protease inhibitors, such as indinavir, ritonavir, nelfinavir, or [3S-[3R\*(1R\*, 2S\*)]]-[3[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-tetrahydro-3-furanyl ester (amprenavir); oxathiolane nucleoside analogues, such as (-)-cis-1-(2-hydroxymethyl)-1,3-oxathiolane 5-yl)-cytosine (lamivudine) or cis-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-5-fluorocytosine (FTC); 3'-deoxy-3'-fluorothymidine; 5-chloro-2',3'-dideoxy-3'-fluorouridine; (-)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; ribavirin; 9-[4-hydroxy-2-(hydroxymethyl)but-1-yl]-guanine (H2G); tat inhibitors, such as 7-chloro-5-(2-pyrrolyl)-3H-1,4-benzodiazepin-2-(H)one (Ro5-3335) or 7-chloro-1,3-dihydro-5-(1H-pyrrol-2-yl)-3H-1,4-benzodiazepin-2-amine (Ro24-7429);

Appln. No. 10/691,333  
Reply dated July 25, 2006  
In response to Office Action dated March 27, 2006

interferons, such as  $\alpha$ -interferon; renal excretion inhibitors such as probenecid; nucleoside transport inhibitors such as dipyridamole; pentoxifylline; N-acetylcysteine (NAC); Procysteine;  $\alpha$ -trichosanthin; phosphonoformic acid; immunomodulators, such as interleukin II or thymosin; granulocyte macrophage colony stimulating factors; erythropoietin; soluble CD<sub>4</sub> and genetically engineered derivatives thereof; non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as nevirapine (BI-RG-587), loviride ( $\alpha$ -APA) or delavuridine (BHAP); phosphonoformic acid; 1,4-dihydro-2H-3,1-benzoxazin-2-ones NNRTIs, such as (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one (L-743,726 or DMP-266); or quinoxaline NNRTIs, such as isopropyl (2S)-7-fluoro-3,4-dihydro-2-ethyl-3-oxo-1(2H)-quinoxalinecarboxylate (HBY1293), wherein said additional agent is administered to said patient as either a separate dosage form or as a single dosage form together with said compound.

33. (New) A compound selected from compound numbers: 26, 27, 28, 29, 30, 31, 32, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 59, 60, 61, 62, 63, 71, 72, 73, 74, 75,

Appln. No. 10/691,333  
Reply dated July 25, 2006  
In response to Office Action dated March 27, 2006

201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212,  
213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224,  
225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236,  
237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248,  
249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260,  
261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272,  
273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284,  
285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296,  
297, 298, 299, 300, 301, 302, 303, 304, 305, 309, 310, 311,  
312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323,  
324, 326, 327, 329, 331, 332, 333, 334, 335, 336, 337, 338,  
339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 351,  
352, 353, 354, 355, 356, 357, 358, 359, 361, 364, 365, 366,  
367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378,  
379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390,  
391, 392, 393, 394, 395, 396, 397 and 398.